Rooted in academic excellence, Epistem's inflammation team has developed an extensive knowledge of the field and applied this experience to a portfolio of preclinical models. The team has been routinely performing in vitro and in vivo studies as a service for the drug discovery industry for over 10 years. This comprehensive understanding of the models and assays offered enables Epistem to offer a consultative approach to study design; advice can be provided on selection of the most suitable model, particularly with reference to the performance of therapeutic agents. Epistem offers a range of in vivo disease models reflecting several key areas of autoimmune disease. Supported by a suite of mechanistic assays, these can provide a valuable and comprehensive data package.

Epistem continues to develop innovative and clinically relevant assays and models to support the drug discovery and development pipeline. Most recently a validated, in vitro model of psoriasis, addressing the need for a clinically relevant model within the industry, was added to the portfolio.

Epistem's Immune Cell Services:

Mechanistic Assays